Jul/10
27
Calibra Medical’s Finesse insulin patch-pen receives FDA clearance for use with Novo Nordisk’s Novolog
0 Comments | Posted by admin in Gene therapy
Calibra Medical announced today it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk’s Novolog® rapid acting insulin. Combining the mealtime therapy-adherence benefits of insulin pumps with the simplicity and affordability of syringes and pens, Calibra’s novel bolus-only patch-pen is a …
« Canon’s second quarterly profit quadruples on global demand for cameras, office equipment
